Arvinas, Inc. Share Price

Arvinas, Inc. Share Price

NASDAQ: ARVN | Small Cap
$7.91
+$0.32 (4.22%) Last updated on 30 Oct, 2026 | 01:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Arvinas, Inc. Stock Performance

Open
$7.70
Prev. Close
$7.58
Circuit Range
N/A
Day Range
$7.70 - $7.96
Year Range
$6.75 - $14.28
Volume
57,667
Average Traded
$7.85

Arvinas, Inc. Share Price Today

As of 30 October 2026, Arvinas, Inc.'s share price is $7.91. The stock opened at $7.70, compared to its previous close of $7.58. During today's trading session, Arvinas, Inc.'s share price traded between $7.70 and $7.96, with an average price of $7.83. Over the past 52 weeks, the stock has recorded a high of $14.28 and a low of $6.75. In terms of performance, Arvinas, Inc.'s share price has declined by 20.07% over the last six months and is down 22.04% on a year-on-year basis.

Arvinas, Inc. Share Price Chart

Line chart of the Arvinas, Inc. price trend over the selected period. The price rose overall, ranging from 7.66 to 7.96, ending at 7.91.
$7.70$7.96
L
Show Current Price
H

Arvinas, Inc. Stock Fundamentals & Key Indicators

Market Cap
$560.46M
PE Ratio (TTM)
53.43
Dividend Yield
0.00%
EPS (TTM)
$0.14
Revenue (TTM)
$262.60B
Return On Equity (TTM)
1.65%
Profit Margin
-30.77%
Debt to Equity
0.00
Quarterly Earnings Growth YoY
582.62%

Arvinas, Inc. Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$41.90$9.50$15.60$249.70
Net Profit-$35.10-$67.40-$57.60$169.40
Net Profit Margin-83.77%-709.47%-369.23%67.84%
Income ChangeN/A-92.02%14.54%394.10%

Arvinas, Inc. Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$131.40$78.50$263.40$262.60
Net Profit-$282.50-$367.30-$198.90-$80.80
Net Profit Margin-214.99%-467.90%-75.51%-30.77%
Income ChangeN/A-30.02%45.85%59.38%

About Arvinas, Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Arvinas, Inc. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$7.75
$7.88
+2.14%
Sep 2026
$9.13
$7.72
-16.40%
Aug 2026
$8.17
$9.23
+15.02%
Jul 2026
$8.42
$8.03
-3.50%
Jun 2026
$8.99
$8.32
-7.35%
May 2026
$10.02
$8.98
-9.20%
Apr 2026
$10.82
$9.89
-6.79%
Mar 2026
$13.21
$10.61
-20.05%
Feb 2026
$13.22
$13.27
-1.04%
Jan 2026
$11.71
$13.41
+12.97%
Dec 2025
$12.24
$11.87
-5.72%
Nov 2025
$10.07
$12.59
+24.16%

ARVN Share Price FAQs